F. Hoffmann-La Roche Ltd.
21 articles with F. Hoffmann-La Roche Ltd.
VABYSMO® (faricimab injection) receives positive CADTH recommendation for the treatment of Diabetic Macular Edema (DME) in adults
Hoffmann-La Roche Limited is pleased to announce that on October 31, 2022, the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee recommended VABYSMO® for public reimbursement.
Health Canada grants Interim Order authorization for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
Hoffmann-La Roche Limited announced that Health Canada has issued an Interim Order authorization for casirivimab and imdevimab, to be administered together, for the treatment of mild to moderate coronavirus disease 2019, confirmed by direct SARS-CoV-2 viral testing, in adults and adolescents who are at high-risk for progressing to hospitalization and/or death.
Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)
New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that significantly reduced the risk of disease progression by 38% compared with chemotherapy (nab-paclitaxel) alone2
F. Hoffmann-La Roche, Johnson & Johnson, and Novartis Compete for a Bigger Share of the Pharmaceuticals Industry, Reports Technavio
The research reports examine the impact of the key players on a global level as well as in specific regions and countries
Various combinations of chemotherapy drugs, along with targeted therapy, are necessary for the optimal treatment of esophageal cancer.
Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects.
The incidence of drug-induced liver injuries is increasing at a significant rate across the world.
There is a growing preference for OTC drugs as they can be bought without a prescription.
Vendors in the cancer biologics market have significantly increased investments for the development of cancer treating biologic molecules.
The increase in smoking and the consumption of tobacco products have resulted in increased incidences of laryngeal cancer.
Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio
According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
Health Canada approves TECENTRIQ® (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
Data show this new option can help some metastatic NSCLC patients live significantly longer
The development and distribution of the Dosing Calculator for emicizumab is sponsored by F. Hoffmann-La Roche.
Roche presented data demonstrating the use of GCP-compliant quantitative MRM mass spectrometry platform in clinical trials
F. Hoffmann-La Roche Ltd. Release: Combination Of Bevacizumab And Lomustine With First Recurrence Of Glioblastoma Prolongs PFS But Not OS
2013 Facility of the Year Awards (FOYA) Winners Announced, Biogen Idec, Inc. (Massachusetts) and F. Hoffmann-La Roche Ltd. Among Them
Acucela Inc. Appoints Former Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. Executive, Jaisim Shah, to the Company’s Board of Directors
Chugai Pharmaceutical Co., Ltd. (Japan) And F. Hoffmann-La Roche Ltd. Release: Overseas Co-Promotion of Actemra(R), a Treatment for Rheumatoid Arthritis
Trimeris, Inc. and F. Hoffmann-La Roche Ltd. Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors